HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
TAPISTRY
This study is now recruiting.
The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts (groups) based on having a specific type of genetic alteration in their tumor. The study includes cohorts for patients whose tumors have genetic alterations in the ROS1, NTRK, PIK3CA, BRAF, or RET genes or a high number of mutations in their tumor.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.
Visit Criteria
This study will enroll patients with advanced solid tumors that have one of the genetic alterations listed above. You will receive one of several investigational targeted therapies or receive immunotherapy with atezolizumab (a drug that helps the immune system fight cancer cells) based on your tumor's genetic alteration.
Participants will frequently come to CHOP Philadelphia for assessments as part of regular oncology care. This includes follow-up visits, blood draws, and scans.
Additional procedures may include:
- Tumor tissue submission
- ECG (electrocardiogram)
- Blood samples
- Diaries
- Questionnaires
- Genetic biomarker testing to better understand the cancer
Treatment may continue until disease progression (tumor growth), unacceptable side effects, or you or your physician choose to discontinue.
Leader
